Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension

Journal of Heart and Lung Transplantation

Volumn 30, Issue 12, 2011, Pages 1327-1333

  Benza, Raymond L ^a   Seeger, Werner ^e   McLaughlin, Vallerie V ^c   Channick, Richard N ^d   Voswinckel, Robert ^e   Tapson, Victor F ^f   Robbins, Ivan M ^g   Olschewski, Horst ^b   Rubin, Lewis J ^d  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f DUKE UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

combination; inhaled treprostinil; open label; PAH; TRIUMPH

Indexed keywords

PLACEBO; PROSTANOID; UNIPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SORE THROAT; THORAX PAIN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HEADACHE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NAUSEA; PHYSICAL ENDURANCE; PIPERAZINES; PURINES; QUALITY OF LIFE; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80655137697     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.08.019     Document Type: Article

References (33)

1. R.L. Benza, D.P. Miller, and M. Gomberg-Maitland Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
2. R.J. Barst, J.S. Gibbs, and H.A. Ghofrani Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl 2009 S78 S84
3. W. Jacobs, A. Boonstra, J.T. Marcus, P.E. Postmus, and A. Vonk-Noordegraaf Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy J Heart Lung Transplant 28 2009 280 284
4. R.N. Channick, H. Olschewski, W. Seeger, T. Staub, R. Voswinckel, and L.J. Rubin Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension J Am Coll Cardiol 48 2006 1433 1437 (Pubitemid 44436826)
5. H. Wilkens, A. Guth, and J. König Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension Circulation 104 2001 1218 1222 (Pubitemid 32848108)
6. V.V. McLaughlin, R.J. Oudiz, and A. Frost Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263 (Pubitemid 44924827)
7. R. Voswinckel, B. Enke, and F. Reichenberger Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies J Am Coll Cardiol 48 2006 1672 1681 (Pubitemid 44528194)
8. V.V. McLaughlin, R.L. Benza, and L.J. Rubin Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 2010 1915 1922
9. T. Gessler, W. Seeger, and T. Schmehl Inhaled prostanoids in the therapy of pulmonary hypertension J Aerosol Med Pulm Drug Deliv 21 2008 1 12
10. R.J. Barst, M. McGoon, and V. McLaughlin Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2003 2119 2125 (Pubitemid 36724255)
11. R.J. Oudiz, N. Gali, and H. Olschewski Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 1971 1981
12. R.L. Benza, R.J. Barst, and N. Galie Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival Chest 134 2008 775 782
13. H. Olschewski, M.M. Hoeper, and J. Behr Long-term therapy with inhaled iloprost in patients with pulmonary hypertension Respir Med 104 2010 731 740
14. M.M. Hoeper, H. Gall, and H.J. Seyfarth Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Eur Respir J 34 2009 132 137
15. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
16. M. Humbert, O. Sitbon, and A. Chaouat Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
17. H. Chen, S.C. Shiboski, and J.A. Golden Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension Am J Respir Crit Care Med 180 2009 468 474
18. R.L. Benza, D.P. Miller, A. Frost, R.J. Barst, A.M. Krichman, and M.D. McGoon Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry Transplantation 90 2010 298 305
19. R.L. Benza, M.H. Park, A. Keogh, and R.E. Girgis Management of pulmonary arterial hypertension with a focus on combination therapies J Heart Lung Transplant 26 2007 437 446 (Pubitemid 46602007)
20. N. Gali, L. Negro, and G. Simonneau The use of combination therapy in pulmonary arterial hypertension: new developments Eur Respir Rev 18 2009 148 153
21. G. Simonneau, L.J. Rubin, and N. Gali Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
22. M. Humbert, R.J. Barst, and I.M. Robbins Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353 359 (Pubitemid 39232254)
23. H.A. Ghofrani, F. Rose, and R.T. Schermuly Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 2003 158 164 (Pubitemid 36760778)
24. H.A. Ghofrani, R. Wiedemann, and F. Rose Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension Ann Intern Med 136 2002 515 522 (Pubitemid 34252285)
25. M.M. Hoeper, H. Leuchte, and M. Halank Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Eur Respir J 28 2006 691 694 (Pubitemid 46331988)
26. O. Sitbon, D.B. Badesch, and R.N. Channick Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 124 2003 247 254 (Pubitemid 36851359)
27. S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jas, and G. Simonneau Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J 27 2006 589 595
28. M. Gomberg-Maitland, C. Dufton, R.J. Oudiz, and R.L. Benza Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective J Am Coll Cardiol 57 2011 1053 1061
29. N. Gali, Lj Rubin, and M. Hoeper Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100 (Pubitemid 351902178)
30. T. Thenappan, and M. Gomberg-Maitland Out with the old, in with the new: an updated risk stratification equation for pulmonary arterial hypertension Expert Rev Cardiovasc Ther 8 2010 739 741
31. V.V. McLaughlin, O. Sitbon, and D.B. Badesch Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249 (Pubitemid 40246523)
32. C. Tueller, H. Stricker, and P. Soccal Epidemiology of pulmonary hypertension: new data from the Swiss registry Swiss Med Wkly 138 2008 379 384 (Pubitemid 351969707)
33. N. Gali, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537